<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04748601</url>
  </required_header>
  <id_info>
    <org_study_id>P255-501</org_study_id>
    <nct_id>NCT04748601</nct_id>
  </id_info>
  <brief_title>Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 4 Study to Evaluate the Efficacy and Safety of Qudexy(R) XR in the Prevention of Migraine in Children 6 to 11 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Upsher-Smith Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Upsher-Smith Laboratories</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11&#xD;
      years of age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline (last 28 days Run-In Period) in the monthly number of headache days during the 8-week Maintenance Period based on the diary.</measure>
    <time_frame>16 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Qudexy XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qudexy XR</intervention_name>
    <description>Extended-Release Capsule</description>
    <arm_group_label>Qudexy XR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Qudexy XR Matching capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is a female or male 6 to 11 years of age, inclusive, at Visit 1 (Screening)&#xD;
&#xD;
          2. Subject weighs at least 17.0 kg and less than 50.0 kg at Visit 1 (Screening) based on&#xD;
             95 percentile weight for the age range.11&#xD;
&#xD;
          3. Subject has at least a 6-month history of headaches consistent with a diagnosis of&#xD;
             migraine with or without aura (International Classification of Headache Disorders, 3rd&#xD;
             Edition [ICHD 3]).&#xD;
&#xD;
          4. Subject had ≥8 self-reported headache days in the 28 days prior to Screening.&#xD;
&#xD;
          5. Subject has a PedMIDAS score &gt;10, indicating at least mild disruption in daily&#xD;
             activities, and &lt;140, indicating extreme disability that may require more&#xD;
             comprehensive, multi component therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has continuous migraines, defined as an unrelenting headache for a 28-day&#xD;
             period.&#xD;
&#xD;
          2. Subject is currently receiving treatment or has used Botulinum toxin (Botox®) within 3&#xD;
             months prior to Visit 1 (Screening).&#xD;
&#xD;
          3. Subject is currently receiving migraine prevention medication and has initiated or&#xD;
             changed the dose within 28 days of Screening or is unwilling to avoid making a change&#xD;
             during the duration of the study.&#xD;
&#xD;
          4. Subject has previously failed an adequate trial of topiramate (at least 3 months&#xD;
             duration at a clinically appropriate dose) for prophylaxis of migraine headache due to&#xD;
             lack of efficacy or AEs.&#xD;
&#xD;
          5. Subject has previously failed an adequate trial of &gt;3 migraine preventative&#xD;
             medications.&#xD;
&#xD;
          6. Subject has a known history of allergic reaction to topiramate or any excipient in&#xD;
             Qudexy XR.&#xD;
&#xD;
          7. Subject has a diagnosis or history of disease that may interfere with safety or&#xD;
             evaluation of the study drug.&#xD;
&#xD;
          8. Subject is currently using an investigational drug or device or has used such within&#xD;
             30 days prior to Visit 1.&#xD;
&#xD;
          9. Subject has begun menses and any of the following:&#xD;
&#xD;
               1. Subject has tested positive for pregnancy; OR&#xD;
&#xD;
               2. Subject is pregnant, planning pregnancy, or lactating; OR&#xD;
&#xD;
               3. Subject is taking an oral hormonal contraceptive (either combined [estrogen and&#xD;
                  progestogen containing] or progestogen-only) and is unable or unwilling to switch&#xD;
                  to an alternative highly effective contraceptive method.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>PPD Laboratories</last_name>
    <phone>1-877-302-2879</phone>
    <email>uslinfo@upsher-smith.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Upsher-Smith Clinical Trial Site #5</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Upsher-Smith Clinical Trial Site #9</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36688</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Upsher-Smith Clinical Trials Site #3</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Upsher-Smith Clinical Trial Site #1</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Upsher-Smith Clinical Trial Site #8</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Upsher-Smith Clinical Trial Site #2</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Upsher-Smith Clinical Trial Site #11</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Upsher-Smith Clinical Trial Site #10</name>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Upsher-Smith Clinical Trial Site #4</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Upsher-Smith Clinical Trial Site #6</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Upsher-Smith Clinical Trials Site #7</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

